Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Eye Divergence in Children Triples Risk of Mental Illness - (DGNews)
    Ginkgo Evaluation of Memory Study Fails to Show Benefit in Preventing Dementia in the Elderly - (DGNews)
    Psychological Interventions Associated With Breast Cancer Survival - (DGNews)
    Safety and Tolerability of Quetiapine in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia: Presented at AACAP - (DGDispatch)
    Effects of Lithium Versus Divalproex in Children and Adolescents With Bipolar I Disorder: Presented at AACAP - (DGDispatch)

    News archive

     Recent webcasts/CME - Psychiatry Other

    Webcasts/CME archive

     Recent cases - Psychiatry Other
      Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
      Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports
      Lithium Intoxication Related Multiple Temporary ECG Changes : A Case Report
      Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
      Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report

      Cases archive
        




      my personal edition > psychiatry other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Atomoxetine Safe and Effective in Long-term, Open-label Treatment of Adults With ADHD: Presented at APA

      By Bruce Sylvester

      SAN FRANCISCO, CA -- May 23, 2003 -- Results of an interim analysis of data from an ongoing trial suggest that long-term atomoxetine treatment is effective and safe in adults with ADHD, researchers report.

      The study was presented here May 22nd at the 2003 Annual Meeting of the American Psychiatric Association.

      "We have lots of short-term data on the efficacy, safety, and tolerability of this drug for ADHD in adults, but this study really begins to distinguish atomoxetine as something that can be used for the long haul for adults," said investigator and co-presenter Dean Jones, PhD, senior scientific investigator at Lilly Research in Indianapolis, Indiana, United States.

      "This open-label follow-up study follows up on acute treatment studies and takes us to the next step in establishing the efficacy, safety, and tolerability of atomoxetine beyond the acute phase," added lead researcher and presenter Thomas Spencer, MD, associate professor of psychiatry at Harvard University Medical School in Boston, Massachusetts.

      The investigators recruited 384 subjects from 2 acute placebo-controlled studies for this open-label extension study.

      The subjects received a mean dose of 94.3 mg/day atomoxetine in the 10-week acute, placebo-controlled studies. Then they went through a wash-out of up to 4 weeks before being treated with atomoxetine 60-120 mg/day (mean dose 96.5 mg/day for an average of 34 weeks) in this ensuing open-label study.

      The researchers used the Conners Adult ADHD Rating Scales: Investigator (CAARS:Inv) as the primary measure of efficacy. "Total ADHD symptom scores decreased from a mean 34.5 at baseline by 15.0 (43.5%). Two thirds of patients achieved at least a 30% decrease in CAARS scores," they reported. "Clinical Global Impression of Severity scores (CGI-S) decreased from 4.7 at baseline by 1.4 (29.8%); 80% achieved at least a 1-point decrease and 47% achieved at least a 2-point decrease in CGI-S scores," they added.

      The atomoxetine drop-out rate for adverse events was 8.5% in the acute studies and 7.8% in the open-label study. Atomoxetine was also generally well tolerated, the authors noted.

      The study was supported by Eli Lilly and Company.


      [Study title: Efficacy and Safety of Atomoxetine in Long-Term, Open-Label Treatment of Adults With ADHD. Abstract NR645]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send